Curis (CRIS) vs Oragenics (OGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oragenics is the larger company by market cap ($2.1 million vs $1.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRIS | OGEN |
|---|---|---|
| Share price | $0.7094 | $0.463 |
| Market cap | $1.72M | $2.09M |
| 1-day change | -3.69% | -7.38% |
| P/E ratio (TTM) | 0.55 | — |
| EPS (TTM) | $1.30 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.60 | $1.45 |
| 52-week low | $0.61 | $0.46 |
| Distance from 52-week high | -97.89% | -68.07% |
| Analyst consensus | none | — |
| Avg. price target upside | +5914.94% | — |
| Average volume | 199.15K | 29.43K |
| Shares outstanding | 2.43M | 4.51M |
| Employees | 20 | 3 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Curis
CRIS stock →Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Healthcare · Biotechnology · 20 employees
About Oragenics
OGEN stock →Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.
Healthcare · Biotechnology · 3 employees
CRIS vs OGEN FAQ
Which is bigger, Curis or Oragenics?
Oragenics (OGEN) is larger, with a market capitalization of $2.09M compared with $1.72M for Curis (CRIS).
Are Curis and Oragenics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.